Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment

Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of norma...

Descripción completa

Detalles Bibliográficos
Autores principales: Subhan, Md Abdus, Yalamarty, Satya Siva Kishan, Filipczak, Nina, Parveen, Farzana, Torchilin, Vladimir P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234032/
https://www.ncbi.nlm.nih.gov/pubmed/34207137
http://dx.doi.org/10.3390/jpm11060571
_version_ 1783713988693983232
author Subhan, Md Abdus
Yalamarty, Satya Siva Kishan
Filipczak, Nina
Parveen, Farzana
Torchilin, Vladimir P.
author_facet Subhan, Md Abdus
Yalamarty, Satya Siva Kishan
Filipczak, Nina
Parveen, Farzana
Torchilin, Vladimir P.
author_sort Subhan, Md Abdus
collection PubMed
description Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
format Online
Article
Text
id pubmed-8234032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82340322021-06-27 Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment Subhan, Md Abdus Yalamarty, Satya Siva Kishan Filipczak, Nina Parveen, Farzana Torchilin, Vladimir P. J Pers Med Review Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy. MDPI 2021-06-18 /pmc/articles/PMC8234032/ /pubmed/34207137 http://dx.doi.org/10.3390/jpm11060571 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Subhan, Md Abdus
Yalamarty, Satya Siva Kishan
Filipczak, Nina
Parveen, Farzana
Torchilin, Vladimir P.
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
title Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
title_full Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
title_fullStr Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
title_full_unstemmed Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
title_short Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
title_sort recent advances in tumor targeting via epr effect for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234032/
https://www.ncbi.nlm.nih.gov/pubmed/34207137
http://dx.doi.org/10.3390/jpm11060571
work_keys_str_mv AT subhanmdabdus recentadvancesintumortargetingviaepreffectforcancertreatment
AT yalamartysatyasivakishan recentadvancesintumortargetingviaepreffectforcancertreatment
AT filipczaknina recentadvancesintumortargetingviaepreffectforcancertreatment
AT parveenfarzana recentadvancesintumortargetingviaepreffectforcancertreatment
AT torchilinvladimirp recentadvancesintumortargetingviaepreffectforcancertreatment

Ejemplares similares